![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
PJ Silver, RE Lepore, B O'Connor, BM Lemp, LT Hamel, RG Bentley and AL Harris
Department of Pharmacology, Sterling-Winthrop Research Institute, Rensselaer, New York.
The purposes of the present study were to quantitate the effects of the cardiotonic/vasodilator milrinone on phosphodiesterase (PDE) isozymes isolated from vascular (aortic) smooth muscle from several species, and to quantitate changes in cellular cyclic AMP (cAMP) content, activation of cAMP protein kinase (cAPK) and vasorelaxation by milrinone in isolated guinea pig aortic smooth muscle. With PDE isozymes isolated from rat (Wistar-Kyoto or spontaneously hypertensive rats), guinea pig, monkey or canine aortic smooth muscle, milrinone is a potent (IC50 = 0.16-0.90 microM) and selective (100 times peak III relative to peak I) peak III inhibitor. The potency of milrinone and other vascular peak III PDE inhibitors parallels their potency as vasorelaxants in isolated guinea pig aortic rings (r = 0.86; P less than .01). Vasorelaxation of phenylephrine-contracted (3 microM) guinea pig aortic rings is accompanied by significant increases in cAMP content or cAPK activation with concentrations of milrinone greater than or equal to 10 microM. Temporally, significant increases in cAMP content accompany significant vasorelaxation; however, activation of cAPK is not significantly increased until at least 1 to 2 min after addition of milrinone. Similar concentration and temporal relationships are seen with the cAMP- related vasorelaxants papaverine and forskolin. As with milrinone, a temporal dissociation between increases in cAMP content and increases in cAPK activity ratio is evident.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  M. Uchida, H. Iida, M. Iida, M. Kumazawa, K. Sumi, M. Takenaka, and S. Dohi Both Milrinone and Colforsin Daropate Attenuate the Sustained Pial Arteriolar Constriction Seen After Unclamping of an Abdominal Aortic Cross-Clamp in Rabbits Anesth. Analg., July 1, 2005; 101(1): 9 - 16. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Wei, C.-Q. Yang, A. Furnary, and G.-W. He Greater vasopressin-induced vasoconstriction and inferior effects of nitrovasodilators and milrinone in the radial artery than in the internal thoracic artery J. Thorac. Cardiovasc. Surg., January 1, 2005; 129(1): 33 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Iida, M. Iida, M. Takenaka, A. Oda, M. Uchida, H. Fujiwara, and S. Dohi The Effects of Alpha-Human Atrial Natriuretic Peptide and Milrinone on Pial Vessels During Blood-Brain Barrier Disruption in Rabbits Anesth. Analg., July 1, 2001; 93(1): 177 - 182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G.-W. He and C.-Q. Yang Vasorelaxant effect of phosphodiesterase-inhibitor milrinone in the human radial artery used as coronary bypass graft J. Thorac. Cardiovasc. Surg., May 1, 2000; 119(5): 1039 - 1045. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. Bowman, H. Haikala, and R. J. Paul Levosimendan, a Calcium Sensitizer in Cardiac Muscle, Induces Relaxation in Coronary Smooth Muscle Through Calcium Desensitization J. Pharmacol. Exp. Ther., January 1, 1999; 288(1): 316 - 325. [Abstract] [Full Text]
|
|
|
|
 |
|
 Y. Gao, J.-F. Tolsa, H. Shen, and J. U. Raj Effect of selective phosphodiesterase inhibitors on response of ovine pulmonary arteries to prostaglandin E2 J Appl Physiol, January 1, 1998; 84(1): 13 - 18. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
